Robert Herman Vonderheide

Robert Herman Vonderheide, MD, DPhil is the Director of the Abramson Cancer Center and John H. Glick Abramson Cancer Center Professor at the Perelman School of Medicine, University of Pennsylvania. An internationally renowned cancer immunotherapy and translational research expert, Dr. Vonderheide focuses on developing novel immunotherapies for pancreatic cancer, melanoma, and breast cancers. His work has established new models for accelerating 'bench to bedside' research translation in oncology.

Dr. Vonderheide's research spans cancer immunology, tumor microenvironment, and immunotherapeutic approaches, with particular emphasis on CD40 agonist antibodies. His extensive publication record includes high-impact studies in journals like Nature, Cell, and Nature Medicine, examining topics ranging from tumor immune microenvironment dynamics to clinical applications of immunotherapies. Recent work has explored ferroptosis of immune cells in the tumor microenvironment and its implications for cancer treatment.

His clinical research program includes multiple innovative clinical trials testing immunotherapeutic approaches, particularly for pancreatic cancer which presents significant challenges for immune-based treatments. Dr. Vonderheide's work bridges fundamental discoveries in tumor immunology with clinical applications, maintaining a strong focus on translating laboratory findings into patient benefit.

As Director of the Abramson Cancer Center, Dr. Vonderheide oversees one of the nation's leading comprehensive cancer centers, driving strategic initiatives in cancer research, treatment, and prevention. His leadership combines deep scientific expertise with clinical experience as a medical oncologist treating adult patients.